SH3PXD2A-AS1 promoted DDP resistance in NSCLC cells by regulating FOXM1 SUCC via SIRT7, offering a promising therapeutic approach for NSCLC. This evidence concerns the gene SH3PXD2A and non-small cell lung carcinoma.